moondance cancer initiative
moondance cancer initiative Company Information
Company Number
12305964
Website
-Registered Address
12 cathedral road, cardiff, CF11 9LJ
Industry
Other human health activities
Telephone
02921113990
Next Accounts Due
September 2025
Group Structure
View All
Shareholders
-0%
moondance cancer initiative Estimated Valuation
Pomanda estimates the enterprise value of MOONDANCE CANCER INITIATIVE at £237.5k based on a Turnover of £520.8k and 0.46x industry multiple (adjusted for size and gross margin).
moondance cancer initiative Estimated Valuation
Pomanda estimates the enterprise value of MOONDANCE CANCER INITIATIVE at £0 based on an EBITDA of £-20k and a 3.94x industry multiple (adjusted for size and gross margin).
moondance cancer initiative Estimated Valuation
Pomanda estimates the enterprise value of MOONDANCE CANCER INITIATIVE at £0 based on Net Assets of £-894 and 2.42x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Moondance Cancer Initiative Overview
Moondance Cancer Initiative is a live company located in cardiff, CF11 9LJ with a Companies House number of 12305964. It operates in the other human health activities sector, SIC Code 86900. Founded in November 2019, it's largest shareholder is unknown. Moondance Cancer Initiative is a young, small sized company, Pomanda has estimated its turnover at £520.8k with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Moondance Cancer Initiative Health Check
Pomanda's financial health check has awarded Moondance Cancer Initiative a 1.5 rating. We use a traffic light system to show it exceeds the industry average on 0 measures and has 5 areas for improvement. Company Health Check FAQs
0 Strong
4 Regular
5 Weak
Size
annual sales of £520.8k, make it smaller than the average company (£714.8k)
- Moondance Cancer Initiative
£714.8k - Industry AVG
Growth
3 year (CAGR) sales growth of 6%, show it is growing at a similar rate (5.8%)
- Moondance Cancer Initiative
5.8% - Industry AVG
Production
with a gross margin of 35.8%, this company has a comparable cost of product (35.8%)
- Moondance Cancer Initiative
35.8% - Industry AVG
Profitability
an operating margin of -4.2% make it less profitable than the average company (5.2%)
- Moondance Cancer Initiative
5.2% - Industry AVG
Employees
with 11 employees, this is below the industry average (18)
11 - Moondance Cancer Initiative
18 - Industry AVG
Pay Structure
on an average salary of £25.6k, the company has an equivalent pay structure (£25.6k)
- Moondance Cancer Initiative
£25.6k - Industry AVG
Efficiency
resulting in sales per employee of £47.3k, this is equally as efficient (£47.3k)
- Moondance Cancer Initiative
£47.3k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Moondance Cancer Initiative
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- Moondance Cancer Initiative
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Moondance Cancer Initiative
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 51 weeks, this is less cash available to meet short term requirements (127 weeks)
51 weeks - Moondance Cancer Initiative
127 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 100.2%, this is a higher level of debt than the average (23.3%)
100.2% - Moondance Cancer Initiative
23.3% - Industry AVG
MOONDANCE CANCER INITIATIVE financials
Moondance Cancer Initiative's latest turnover from December 2023 is estimated at £520.8 thousand and the company has net assets of -£894. According to their latest financial statements, Moondance Cancer Initiative has 11 employees and maintains cash reserves of £565.2 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|
| Turnover | ||||
| Other Income Or Grants | ||||
| Cost Of Sales | ||||
| Gross Profit | ||||
| Admin Expenses | ||||
| Operating Profit | ||||
| Interest Payable | ||||
| Interest Receivable | ||||
| Pre-Tax Profit | ||||
| Tax | ||||
| Profit After Tax | ||||
| Dividends Paid | ||||
| Retained Profit | ||||
| Employee Costs | ||||
| Number Of Employees | 11 | 11 | 9 | 10 |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|
| Tangible Assets | 1,799 | 2,345 | 2,894 | 2,417 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 1,799 | 2,345 | 2,894 | 2,417 |
| Stock & work in progress | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 |
| Misc Debtors | 3,114 | 1,857 | 373,440 | 0 |
| Cash | 565,156 | 398,638 | 46,619 | 769,303 |
| misc current assets | 0 | 0 | 0 | 0 |
| total current assets | 568,270 | 400,495 | 420,059 | 769,303 |
| total assets | 570,069 | 402,840 | 422,953 | 771,720 |
| Bank overdraft | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 |
| other current liabilities | 570,963 | 405,427 | 427,515 | 776,283 |
| total current liabilities | 570,963 | 405,427 | 427,515 | 776,283 |
| loans | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 |
| total liabilities | 570,963 | 405,427 | 427,515 | 776,283 |
| net assets | -894 | -2,587 | -4,562 | -4,563 |
| total shareholders funds | -894 | -2,587 | -4,562 | -4,563 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|
| Operating Activities | ||||
| Operating Profit | ||||
| Depreciation | 1,868 | 1,554 | 1,085 | |
| Amortisation | 0 | 0 | 0 | |
| Tax | ||||
| Stock | 0 | 0 | 0 | 0 |
| Debtors | 1,257 | -371,583 | 373,440 | 0 |
| Creditors | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 165,536 | -22,088 | -348,768 | 776,283 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 |
| Cash flow from operations | ||||
| Investing Activities | ||||
| capital expenditure | ||||
| Change in Investments | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||
| Financing Activities | ||||
| Bank loans | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 |
| share issue | ||||
| interest | ||||
| cash flow from financing | ||||
| cash and cash equivalents | ||||
| cash | 166,518 | 352,019 | -722,684 | 769,303 |
| overdraft | 0 | 0 | 0 | 0 |
| change in cash | 166,518 | 352,019 | -722,684 | 769,303 |
moondance cancer initiative Credit Report and Business Information
Moondance Cancer Initiative Competitor Analysis
Perform a competitor analysis for moondance cancer initiative by selecting its closest rivals and benchmarking them against 12 key performance metrics.
moondance cancer initiative Ownership
MOONDANCE CANCER INITIATIVE group structure
Moondance Cancer Initiative has no subsidiary companies.
Ultimate parent company
MOONDANCE CANCER INITIATIVE
12305964
moondance cancer initiative directors
Moondance Cancer Initiative currently has 7 directors. The longest serving directors include Mr Geoffrey Graham (Nov 2019) and Mr Henry Engelhardt (Feb 2020).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Geoffrey Graham | United Kingdom | 67 years | Nov 2019 | - | Director |
| Mr Henry Engelhardt | 66 years | Feb 2020 | - | Director | |
| Ms Elisabeth Neil | United Kingdom | 56 years | Feb 2020 | - | Director |
| Mrs Diane Briere De I'Isle-Engelhardt | United Kingdom | 66 years | Feb 2020 | - | Director |
| Mr Thomas Crosby | United Kingdom | 59 years | Feb 2020 | - | Director |
| Dr David Gillen | United Kingdom | 55 years | Jun 2023 | - | Director |
| Prof Kamila Hawthorne | England | 64 years | Dec 2023 | - | Director |
P&L
December 2023turnover
520.8k
-1%
operating profit
-21.8k
0%
gross margin
35.8%
+3.04%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
-894
-0.65%
total assets
570.1k
+0.42%
cash
565.2k
+0.42%
net assets
Total assets minus all liabilities
moondance cancer initiative company details
company number
12305964
Type
Private Limited by guarantee without Share Capital Exempt from using Limited
industry
86900 - Other human health activities
incorporation date
November 2019
age
5
accounts
Small Company
ultimate parent company
previous names
N/A
incorporated
UK
address
12 cathedral road, cardiff, CF11 9LJ
last accounts submitted
December 2023
moondance cancer initiative Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to moondance cancer initiative.
moondance cancer initiative Companies House Filings - See Documents
| date | description | view/download |
|---|
